Adults 18 to 75, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Difference in Ketone Bodies Formation After Single Dose of Liraglutide and DapagliflozinPrimary· 8 hours
To compare levels of ketone bodies beta-hydroxybutyrate in plasma following a single dose treatment of either liraglutide 1.8mg,dapagliflozin 10mg or placebo in insulinopenic state.
Group
Value
95% CI
Liraglutide 1.8 mg
0.08
± 0.05
Placebo
0.25
± 0.05
Dapagliflozin
0.21
± 0.05
Change in Glucagon Levels.Secondary· 8 hours
This secondary endpoint compares change in glucagon concentrations (in pg/ml) from baseline at 8 hours following liraglutide and dapagliflozin compared to placebo
Group
Value
95% CI
Liraglutide 1.8 mg
-19
± 14
Placebo
1
± 6
Dapagliflozin
-15
± 5
Change in Free Fatty Acid (FFA) ConcentrationsSecondary· 8 hours
This secondary endpoint compares the change in FFA concentrations (mM) from baseline at 8 hours following liraglutide and dapagliflozin compared to placebo
Group
Value
95% CI
Liraglutide 1.8 mg
0.1
± 0.06
Placebo
0.17
± 0.06
Dapagliflozin
0.11
± .06
Change in Ghrelin ConcentrationsSecondary· 8 Hours
This secondary endpoint compares the change in ghrelin concentrations (pg/ml) from baseline at 8 hours following liraglutide and dapagliflozin compared to placebo
Group
Value
95% CI
Liraglutide 1.8 mg
-32
± 28
Placebo
66
± 29
Dapagliflozin
32
± 26
Sponsor's own description
1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state.
2. To compare plasma levels of free fatty acid, glucagon, hs-CRP, Ll-6 and IL-1 before and after administration of liraglutide/placebo.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT05794581 — A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
· Phase 1
· completed
NCT05029076 — Human Bioequivalence Test of Liraglutide Injection
· Phase 1
· completed
Other recruiting trials for Type 1 Diabetes
Currently open trials in the same condition.
NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On
· Phase 1, PHASE2
· recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care
· recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
· recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1
· NA
· recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.
· NA
· recruiting
Other University at Buffalo trials
Trials by the same sponsor.
NCT06324630 — Implementation of Innovative Food Prescription Programs in Older Adults
· NA
· completed
NCT06681909 — University At Buffalo Campus Veggie Van Mobile Market
· active not recruiting
NCT07088003 — Yoga as Mindful Movement: A Randomized Controlled Trial
· NA
· completed
NCT04557566 — ED Recovery Course Online RCT
· NA
· completed
NCT03920995 — Multi-center Database Registry to Study Thalamus Changes Using AI in MS
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University at Buffalo
Last refreshed: 29 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02777073.